The following full text is a publisher's version.

For additional information about this publication click this link.
https://hdl.handle.net/2066/229882

Please be advised that this information was generated on 2021-06-07 and may be subject to change.
Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney

Gijs A. C. Franken | Anastasia Adella | René J. M. Bindels | Jeroen H. F. de Baaij

Abstract

Hypomagnesaemia is a common feature of renal Na⁺ wasting disorders such as Gitelman and EAST/SeSAME syndrome. These genetic defects specifically affect Na⁺ reabsorption in the distal convoluted tubule, where Mg²⁺ reabsorption is tightly regulated. Apical uptake via TRPM6 Mg²⁺ channels and basolateral Mg²⁺ extrusion via a putative Na⁺-Mg²⁺ exchanger determines Mg²⁺ reabsorption in the distal convoluted tubule. However, the mechanisms that explain the high incidence of hypomagnesaemia in patients with Na⁺ wasting disorders of the distal convoluted tubule are largely unknown. In this review, we describe three potential mechanisms by which Mg²⁺ reabsorption in the distal convoluted tubule is linked to Na⁺ reabsorption. First, decreased activity of the thiazide-sensitive Na⁺/Cl⁻ cotransporter (NCC) results in shortening of the segment, reducing the Mg²⁺ reabsorption capacity. Second, the activity of TRPM6 and NCC are determined by common regulatory pathways. Secondary effects of NCC dysregulation such as hormonal imbalance, therefore, might disturb TRPM6 expression. Third, the basolateral membrane potential, maintained by the K⁺ permeability and Na⁺-K⁺-ATPase activity, provides the driving force for Na⁺ and Mg²⁺ extrusion. Depolarisation of the basolateral membrane potential in Na⁺ wasting disorders of the distal convoluted tubule may therefore lead to reduced activity of the putative Na⁺-Mg²⁺ exchanger SLC41A1. Elucidating the interconnections between Mg²⁺ and Na⁺ transport in the distal convoluted tubule is hampered by the currently available models. Our analysis indicates that the coupling of Na⁺ and Mg²⁺ reabsorption may be multifactorial and that advanced experimental models are required to study the molecular mechanisms.

KEYWORDS
distal convoluted tubule, hypomagnesaemia, ion transport, kidney, magnesium, sodium
INTRODUCTION

The distal convoluted tubule (DCT) is an essential nephron segment for blood pressure regulation and potassium (K+) homeostasis. In the DCT, 10% of the filtered sodium (Na+) and magnesium (Mg2+) is reabsorbed in a transcellular mechanism, which is highly regulated by endocrine regulation. Genetic and acquired diseases of the DCT segment are therefore associated with renal Na+ and Mg2+ wasting. Notably, hereditary Na+ wasting disorders often present with hypomagnesaemia (serum Mg2+ <0.7 mmol L−1), a condition in which serum Mg2+ concentrations are below normal (normal 0.7-1.05 mmol L−1). However, the mechanisms that explain hypomagnesaemia in these patients are largely unidentified. In this review, we present three hypotheses of mechanisms underlying the hypomagnesaemia caused by genetic DCT Na+ wasting disorders. In addition, we provide detailed descriptions on Na+ and Mg2+ reabsorption in the DCT.

1.1 Mechanisms of Na+ reabsorption in the DCT

The DCT is responsible for the reabsorption of 5-10% of the filtered Na+ load. Early micropuncture studies demonstrate that this may increase up to 30%-45% when required, showing the enormous compensatory capacity of this segment. In the early DCT, apical Na+ uptake is facilitated by the thiazide-sensitive sodium chloride (Cl−) co-transporter (NCC) (Figure 1). Given that NCC is the sole Na+ transporter in the luminal plasma membrane in the DCT, decreased NCC activity results in renal Na+ wasting. Basolateral Na+ extrusion towards the peritubular fluid depends on Na+-K+-ATPase activity. The activity of this pump and the high permeability of K+ via Kir4.1/Kir5.1 K+ channels set the basolateral membrane potential difference that typically ranges between −60 and −90 mV in the DCT. Na+-K+-ATPase function depends directly on Mg2+-bound ATP (Mg-ATP) availability, and indirectly on free Mg2+ and the back-leak of K+. This so-called “pump-leak coupling” of K+ recycling between Na+-K+-ATPase is essential to maximise the Na+ reabsorption capacity of the DCT.

Na+ reabsorption in the DCT depends on the number of NCC transporters present in the plasma membrane and subsequent activation by phosphorylation. Three residues in the intracellular N-terminal region of NCC can be phosphorylated by Ste20-like proline-alanine–rich kinase (SPAK) and oxidative stress response kinase 1 (OSR1). In turn, SPAK and OSR1 are activated by With-No-Lysine (WNK).
kinases. WNK kinases are, therefore, the main target of pathways regulating Na⁺ reabsorption including, but not limited to, angiotensin II, vasopressin, insulin and aldosterone. Mutations in WNK1 and WNK4 are associated with familial hyperkalaemic hypertension (FHHt) or pseudohypoaldosteronism type II (PHAII) (OMIM: 145260) as a result of increased NCC activity. Of note, most PHAII patients have mutations in ubiquitin ligase Cullin 3 (CUL3) or its adaptor protein Kelch-like-3 (KLHL3). The CUL3-KLHL3 complex is essential for the ubiquitination of WNK1 and WNK4, thereby regulating their expression levels and indirectly determining NCC activity.

Recently, plasma K⁺ levels were identified as a major physiological determinant of NCC activity. A multitude of in vitro and in vivo studies have demonstrated that low extracellular K⁺ levels increase NCC phosphorylation independently of Na⁺ and angiotensin II levels. These findings have resulted in the current model in which Kir4.1/Kir5.1 channels serve as a K⁺ sensor. Kir4.1/Kir5.1 hyperpolarises the membrane and decreases the intracellular Cl⁻ concentration. Crystallography studies revealed that Cl⁻ binds to WNK kinases and thereby inhibits their autophosphorylation/activation. Therefore, low [K⁺], ultimately results in the increase in NCC phosphorylation and thereby enhances Na⁺ reabsorption. This K⁺ sensing mechanism is the main determinant of the Na⁺ delivery to the aldosterone-sensitive distal nephron, where the epithelial Na⁺ channel ENaC-mediated Na⁺ uptake is coupled to K⁺ secretion via renal outer medullar K⁺ channel (ROMK). Na⁺ reabsorption in the DCT lowers the Na⁺ load in the CD, which allows retention of K⁺ via decreased ROMK-mediated K⁺ secretion. As such, the DCT determines the downstream K⁺ handling and is an essential mediator of K⁺ homeostasis.

1.2 | Mechanisms of Mg²⁺ reabsorption in the DCT

The DCT plays a crucial role in determining the urinary Mg²⁺ excretion as subsequent nephron segments cannot reabsorb Mg²⁺ from the pro-urine.Transient receptor potential melastatin 6 (TRPM6) channels facilitate Mg²⁺ influx from the lumen (Figure 1). Each protein consists of 6 transmembrane domains and forms a tetramer to become functional at the apical membrane. Recent data suggest that TRPM6 requires heterotetramer formation with its family member TRPM7 to function. The chemical gradient for Mg²⁺ is negligible (0.2-1.0 mmol L⁻¹ in the lumen vs 0.5-1.0 mmol L⁻¹ intracellular) and the TRPM6-mediated Mg²⁺ influx is, therefore, dependent on the voltage gradient across the luminal membrane. It is postulated that this is orchestrated by the luminal voltage-gated K⁺ channel Kv1.1. The activity of TRPM6 is regulated by several external and internal factors, such as EGF, insulin, oestrogens, dietary Mg²⁺ intake and intracellular Mg²⁺ concentrations. Inactivating mutations in TRPM6 have been associated with hypomagnesaemia with secondary hypocalcaemia (HSH; OMIM: 602014). In HSH patients, serum Mg²⁺ levels drop below 0.3 mmol L⁻¹ and endanger proper brain development if left untreated.

Unlike the influx of Mg²⁺ from the luminal side, the players facilitating Mg²⁺ efflux towards the blood compartment have not yet been conclusively elucidated. Two main mechanisms have been proposed, although they remain controversial. Mg²⁺ efflux towards the blood compartment requires an anti-porter or ATPase, since no chemical gradient exists for Mg²⁺ while the voltage gradient favours Mg²⁺ influx. The presence of a Na⁺-Mg²⁺ exchanger has been demonstrated as the mechanism for Mg²⁺ efflux in multiple cell types. Although the molecular identity of the putative Na⁺-Mg²⁺ exchanger has not been definitively identified, the most promising candidate is the solute carrier family 41 member 1 (SLC41A1). This transmembrane protein is located at the basolateral domain of the DCT and has been shown to facilitate Mg²⁺ efflux. Mutations in the gene have been observed in one patient of a consanguineous family suffering from a nephropathies-like phenotype, although these patients do not experience hypomagnesaemia or renal wasting of magnesium. An alternative candidate for basolateral Mg²⁺ extrusion is cyclin M2 (CNNM2). This transmembrane protein localizes specifically to the basolateral compartment of the DCT and contains two cystathionine-beta-synthase (CBS) domains capable of binding Mg²⁺-ATP. Inactivating mutations have been implicated in a syndrome that prominently features hypomagnesaemia and renal magnesium wasting (OMIM: 613882). Although CNNM2 has been proposed as the Na⁺-Mg²⁺ exchanger in the DCT, this hypothesis remains to be confirmed experimentally.
| Syndrome | Classification | Gene | Protein | Type of mutation | Aldosterone | Blood pH | Ca²⁺ | Cl⁻ | K⁺ | Mg²⁺ | Na⁺ | References |
|----------|----------------|------|---------|------------------|-------------|----------|-------|------|-----|-------|-----|------------|
| Salt-wasting disorders | | | | | | | | | | | | |
| TAL-associated | | | | | | | | | | | | |
| Bartter syndrome | Type I | SLC12A1 | NKCC2 | LoF | ↑ | Alkalosis | = | = | ↓ | = | = | ↑ | = | ↑ | ↑ | 71,73-75 |
| Bartter syndrome | Type II | KCNJ1 | ROMK | LoF | ↑ | Alkalosis | = | = | ↓ | = | = | = | ↑ | = | ↑ | 72-75 |
| Bartter syndrome | Type IV | BSND | Barttin | LoF | ↑ | Alkalosis | = | = | ↓ | = | = | = | = | = | = | 70,73-75 |
| DCT-associated | | | | | | | | | | | | |
| Bartter syndrome | Type III | CLCNKB | ClC-Kb | LoF | =/↑ | Alkalosis | = | = | ↓ | = | = | = | = | = | ↑ | 73-75,157 |
| EAST/SeSAME syndrome | | | | | | | | | | | | |
| Gordon syndrome or pseudohypoaldosteronism II | | | | | | =/↑ | Alkalosis | = | = | ↓ | = | = | = | =/↑ | = | = | = | 28,160,161 |
| Mg²⁺-wasting disorders³ | | | | | | | = | = | ↓ | = | = | = | ↑ | = | = | = | = | 29,162,163 |
| Autosomal dominant hypomagnesaemia | | | | | | | = | = | ↓ | = | = | = | ↑ | = | = | = | = | 51,164 |
| Hypomagnesaemia with secondary hypocalcaemia syndrome | | | | | | | = | = | ↓ | = | = | = | = | = | = | ↑ | 54,55,165 |
| Hypomagnesaemia, seizure and intellectual disability syndrome | | | | | | | = | = | ↓ | = | = | = | = | = | = | ↑ | 60,62 |
| Isolated hypomagnesaemia | | | | | | | = | = | ↓ | = | = | = | = | = | = | ↑ | 142,143 |
| | | | | | | | = | = | ↓ | = | = | = | = | = | = | ↑ | 144 |

Abbreviations: ↑ indicates an increase; ↓ indicates a decrease; = indicates normality; ATP1A1, α1-subunit of Na⁺-K⁺-ATPase; Barttin, Bartter syndrome, infantile, with sensorineural deafness; BSND, Barttin CLCNK type accessory beta subunit; CLCNKB & ClC-Kb, voltage-gated Cl⁻ channel; CNNM2, cyclin M2; CUL3, ubiquitin ligase Cullin 3; FXYD2, γ-subunit of Na⁺-K⁺-ATPase; GoF, gain of function; KCNA1 & Kv1.1, K⁺ voltage-gated channel family A member 1; KCNJ1, K⁺ voltage-gated channel family J member 1; KCNJ10, K⁺ inwardly rectifying channel subunit J member 10; Kir4.1, K⁺ inwardly rectifying channel 4.1; KLHL3, kelch-like-3; LoF, loss of function; NCC, Na⁷Cl⁻ cotransporter; NKCC2, Na-K-2Cl cotransporter; ROMK, renal outer medullary K⁺ channel; SLC12A1, solute carrier 12 member 1; SLC12A3, solute carrier 12 member 3; TRPM6, transient receptor potential melastatin 6; WNK1, with no lysine kinase 1; WNK4, with no lysine kinase 4.

³ A full overview of DCT associated Mg²⁺-wasting disorder can be found in Viering et al (2017).¹⁵₆
Barter syndrome is a hereditary disorder of Na\(^+\) reabsorption in the TAL, which is characterized by hypokalaemia, metabolic alkalosis, polyuria, hypercalciuria and nephrocalcinosis. Barter syndrome is caused by mutations in SLC12A1 encoding NKCC2 (type I), KCNJ1 encoding ROMK (type II), CLCNKB encoding ClC-Kb (type III) or BSDN encoding Barttin (type IV) (OMIM: 601678, 241200, 607364 and 602522, respectively).\(^{70-75}\) Notably, hypomagnesaemia is not uniformly present in Barter syndrome (Table 1). Hypomagnesaemia is generally only observed in Barter syndrome type III and IV, in which patients can present with features of antenatal Barter as well as Gitelman syndrome.\(^{76}\) Mice deficient for ClC-Kb indeed showed hyppermagnesauria, in line with the observed decreased serum Mg\(^{2+}\) concentrations in patients with type III Barter. Generally, this phenomenon is explained by the expression pattern of ClC-Kb and Barttin, which are not limited to TAL, but also present in the DCT. In line with this observation, the incidence of furosemide, an inhibitor of NKCC2, rarely results in hypomagnesaemia.\(^{77-79}\) Indeed, in an animal study, furosemide treatment did not result in hypomagnesaemia and was associated with increased TRPM6 expression in the DCT.\(^{80}\) Altogether we, therefore, hypothesise that the presence of hypomagnesaemia depends on reduced Na\(^+\) reabsorption in the DCT.

Congenital syndromes that impair Mg\(^{2+}\) reabsorption in the DCT, such as TRPM6 and CNNM2-associated disorders, do not involve disturbances of Na\(^+\) or K\(^+\) homeostasis.\(^{54,55,60,62}\) Drugs that reduce TRPM6 activity, eg EGFR inhibitors, cause hypomagnesaemia, but are not associated with increased Na\(^+\) wasting.\(^{32,81-84}\) Only drugs that affect both TRPM6 and NCC activity such as rapamycin and calcineurin inhibitors concomitantly result in Mg\(^{2+}\) and Na\(^+\) wasting.\(^{85-87}\) Altogether, these findings suggest that Na\(^+\) reabsorption affects Mg\(^{2+}\) reabsorption in the DCT but not vice versa. From a physiological point of view, this would mean that the Mg\(^{2+}\) reabsorption would be proportional to the Na\(^+\) reabsorption in the DCT. However, since Mg\(^{2+}\) homeostasis is also dependent on reabsorption in other nephron segments, bone storage and intestinal absorption, such correlations are rather complex to determine.

Given that patients with loss-of-function mutations in NCC or long-term thiazide treatment suffer from hypomagnesaemia\(^{66,67}\) and that both SPAK\(^{-/-}\) and NCC\(^{-/-}\) mice develop hypomagnesaemia,\(^{13,88-91}\) it is generally accepted that Mg\(^{2+}\) reabsorption is affected by Na\(^+\) reabsorption in the DCT. However, the nature of this relationship and the molecular mechanisms explaining this phenomenon are largely unknown. In the following part of this review, we will critically assess three mechanisms that may explain the link between Mg\(^{2+}\) reabsorption and NCC activity.

### 2.1 Does DCT remodelling affect Mg\(^{2+}\) reabsorption?

NCC\(^{-/-}\) mice often serve as a model for Gitelman syndrome because they display similar features as patients, such as increased renin mRNA levels in kidney, hypomagnesaemia and hypocalciuria.\(^{13,92}\) Since the first generation of NCC\(^{-/-}\) mouse, several groups have demonstrated atrophy of the DCT region,\(^{12,13}\) suggesting that NCC activity is essential for DCT cell survival. Interestingly, TRPM6 expression is lowered in NCC\(^{-/-}\) mice and is accompanied by renal wasting of Mg\(^{2+}\),\(^{92}\) which potentially could be explained by structural differences in the DCT segment (Figure 2). Recently, Schnoz et al shown that NCC\(^{-/-}\) mice essentially lack DCT1 cells which has been attributed to an increase in apoptosis.\(^{93}\) Likewise, a mouse model suffering mutations found in Gitelman syndrome shown reduced early DCT mass.\(^{94}\) Consequently, a decrease in TRPM6 expression on protein level was observed. Yet, it cannot be excluded that the DCT cells, although less numerous, are capable to compensate by increasing TRPM6 activity at the cellular level.

Likewise, increased phosphorylation of NCC via gain-of-function (GoF) mutations in WNK4 in mice, which leads to PHAII in humans, has been shown to elongate the DCT and associated with a mild increase in serum Mg\(^{2+}\) levels.\(^{95}\) Similarly, mice with constitutively active SPAK (CA-SPAK) display DCT hyperplasia and hypertrophy,\(^{96}\) while depletion of SPAK was associated with reduced DCT mass.\(^{89}\) This suggests that NCC activity, ie Na\(^+\) reabsorption in the DCT, is directly linked to DCT length. Interestingly, the GoF-WNK4 mouse model shown impaired K\(^+\) secretion and hyperkalaemia which was attributed to increased NCC and reduced ENaC activity, resulting in diminished ROMK-mediated K\(^+\) excretion.\(^{95}\) In contrast, it was reported that loss of Kir4.1, which leads to reduced NCC activity, is accompanied by a shortening of the DCT.\(^{97}\) In line, dietary K\(^+\) restriction resulted in increased phosphorylation of NCC as a result of increased Kir4.1 activity, and was accompanied by elongation of the DCT.\(^{97}\) Interestingly, long-term use of furosemide, the inhibitor of NKCC2 in the TAL, has been associated with hyperplasia and hypertrophy in the DCT, CNT and CD.\(^{11,98}\) Nevertheless, furosemide treatment generally does not result in hypermagnesaemia.\(^{77,79,80}\) However, it should be noted that furosemide decreases the driving force for Mg\(^{2+}\) reabsorption in the TAL, which may be compensated by increased Mg\(^{2+}\) reabsorption in the DCT. Moreover, increased renal Mg\(^{2+}\) reabsorption can be counteracted by reduced intestinal Mg\(^{2+}\) absorption or increased bone Mg\(^{2+}\) storage.

The mechanism by which altered Na\(^+\) or K\(^+\) load cues the DCT for adaptation remains obscure. It can, however, be hypothesized that DCT length is coupled to energy demand. The epithelial cells are packed with mitochondria owing to the
need of ATP for proper Na\(^+\)-K\(^+\)-ATPase functioning. Lowered Na\(^+\) loads to the DCT will result in a decreased basolateral Na\(^+\) efflux and a decreased ATP requirement. Indeed, NCC\(^{-/-}\) DCT cells had decreased mitochondrial mass.\(^{13}\) In line, rats treated with thiazides demonstrated a decrease in cellular mitochondrial content, which was concomitant with a stimulation of apoptosis.\(^{99}\) Similarly, rats on enriched Na\(^+\) diets or on furosemide showed an increase in DCT volume and increase in mitochondrial content,\(^{11}\) associated with a higher metabolic demand of the cells.\(^{100,101}\) Mitochondrial biogenesis, the process of producing more functional mitochondria, can be stimulated via pharmacological agents, such as AICAR or Rapamycin.\(^{102}\) It would be interesting to investigate if, under the right conditions, DCT shortening can be rescued via intervention of this mTOR-AMPK pathway. It should be mentioned that Mg\(^{2+}\) reabsorption via TRPM6 has also been shown in vitro to be sensitive to mitochondrial activity. Electrophysiological analyses have shown that TRPM6 activity can be inhibited by H\(_2\)O\(_2\), a by-product of mitochondrial activity.\(^{103}\) Yet, other models are required to test its validity in vivo.

However, patients suffering hypertension and treated with thiazides already display an increased renal Mg\(^{2+}\) leakage within hours, suggestive that there are also acute responses at hand, eg hormonal, rather than DCT remodelling that modulate Mg\(^{2+}\) reabsorption in the DCT.\(^{104}\)

### 2.2 Is Mg\(^{2+}\) reabsorption regulated via the same pathways that regulate the NCC?

The NCC phosphorylation cascade is well-known for its sensitivity to hormones such as angiotensin II, aldosterone and insulin in order to maintain blood pressure.\(^{2-6}\) Interestingly, a number of paracrine and endocrine factors have been shown to regulate TRPM6.\(^{7-10}\) Therefore, it can be speculated that there are common endocrine pathways that regulate both Na\(^+\) and Mg\(^{2+}\) reabsorption.

Aldosterone has been described as a regulator of both renal Na\(^+\) as well as Mg\(^{2+}\) reabsorption.\(^{2-4,105-107}\) To regulate NCC, aldosterone targets the mineralocorticoid steroid receptor (MR) and stimulates SGK1 phosphorylation, which halts the E3 ubiquitin ligase NEDD4-2, resulting in increased NCC activation.\(^{108}\) Moreover, it has been shown that aldosterone also increases the activity of WNK/SPAK axis indirectly by modulating blood K\(^+\) levels, although it is not fully understood how the two pathways interact (Figure 3).\(^{2-4,109}\) Although the direct effect of this axis on the activity of TRPM6 has never been determined in vitro, van Megen et al have shown that DCT-specific CA-SPAK mice, in which NCC activity is increased, exhibit normomagnesae mia. Moreover, renal TRPM6 mRNA expression level was not altered.\(^{110}\) This suggests that TRPM6 regulation does not
involve the WNK/SPAK axis and more direct pathways are likely involved.

Nevertheless, hypomagnesaemia and increased renal Mg\(^{2+}\) wasting have been described in patients suffering from hyperaldosteronism owing to the presence of primary adrenocarcinoma.\(^{105,111}\) In rat models, aldosterone administration increased Mg\(^{2+}\) and Ca\(^{2+}\) levels in the urine and faeces, which was reversible upon spironolactone treatment, an antagonist of the aldosterone receptor.\(^{112,113}\) It is, however, not clear whether changes in Mg\(^{2+}\) reabsorption are directly linked to decreased DCT-mediated electrolyte reabsorption or if it is a systemic effect caused by changes in blood pressure.\(^{112}\) For instance, aldosterone administration in C57B6 mice was associated with decreased renal TRPM7 expression independent of changes in blood pressure, suggesting a direct effect of aldosterone on DCT Mg\(^{2+}\) reabsorption.\(^{114}\) On the other hand, hypertensive mice with an innate lowered serum Mg\(^{2+}\) levels displayed decreased TRPM6 expression upon aldosterone treatment, suggesting that these effects might be mediated by the changes in the extracellular volume.\(^{115}\) In addition to the difference in basal blood pressure levels, it is also important to note that the two mice models have different genetic backgrounds. Therefore, interpretation of results and conclusions drawing should be taken cautiously.

Currently, assessing the effect of aldosterone on TRPM6 function remains difficult because of the lack of cell models that express the protein endogenously. Nevertheless, the
effect of aldosterone treatment on TRPM7 expression in the kidney has been studied in vitro. For instance, TRPM7 expression was increased via the SGK1-mediated phosphorylation of the TRPM7-kinase domain upon exposure of aldosterone in HEK293 cells and mediated Mg\(^{2+}\) influx, although these effects were not acute.\(^{116,117}\) Yet, it is still not elucidated whether these results are specific for TRPM7 or could potentially be extended to TRPM6.\(^{116}\) Consequently, the effect of aldosterone on Mg\(^{2+}\) reabsorption in the kidney remains to be experimentally confirmed.

Interestingly, recent studies have disclosed that dietary depletion of Mg\(^{2+}\) can directly affect NCC-mediated Na\(^{+}\) reabsorption. Firdaus et al demonstrated that dietary Mg\(^{2+}\) restriction decreased the renal NCC expression.\(^{118}\) Unlike with K\(^{+}\) restriction diets, which leads to increased NCC phosphorylation via increased Kir4.1 activity,\(^{119}\) Mg\(^{2+}\) restriction led to degradation of NCC, possibly via the ubiquitin E3 ligase NEDD4-2 (Figure 4). Mice deficient for NEDD4-2 exhibited resistance to dietary Mg\(^{2+}\)-dependent NCC degradation. More recently, the same authors published a proposed mechanism by which NEDD4-2 regulates Kir4.1/Kir5.1 function, which indirectly affects the intracellular Cl\(^{-}\) concentration, and thereby the WNK/SPAK-axis.\(^{120}\) Whether the effects of Mg\(^{2+}\) were directed via Kir4.1/Kir5.1 was not explored. Free Mg\(^{2+}\) and Mg\(^{2+}\) bound ATP (Mg-ATP) are known factors that inhibit TRPM6 function, as they can directly block channel activity.\(^{121,122}\) How (intracellular) Mg\(^{2+}\) levels regulate NCC expression in the DCT should be experimentally investigated, since this could also aid in the understanding why patients suffering HSH or HSMR syndrome do not have altered Na\(^{+}\) reabsorption in the DCT.

Insulin stimulates Na\(^{+}\) reabsorption in the kidney, as notoriously known by the increased risk of hypertension in diabetic type II patients.\(^{123,124}\) Apart from increasing Na\(^{+}\) transport in the proximal tubule and loop of Henle,\(^{125,126}\) insulin has been shown to both modulate NCC and TRPM6 activity by a PI3K (phosphoinositide 3 kinases), mTORC2 (mechanistic target of rapamycin complex 2) and AKT1 (AKT serine/threonine kinase 1)-dependent phosphorylation cascade (Figure 3).\(^{5,6,10}\) Although impaired glucose metabolism and insulin resistance have been described in Gitelman patients,\(^{127-129}\) the minor changes in plasma insulin levels make it unlikely that insulin is responsible for hypomagnesaemia in Na\(^{+}\) wasting disorders.

In addition to insulin and aldosterone, oestrogens have been shown to regulate TRPM6 and NCC expression.\(^{130-135}\) For example, oestrogens increase renal NCC expression and activity via its phosphorylation\(^{136,137}\) and TRPM6 mRNA levels in animal models.\(^{53,138}\) Yet, no reports have been found that show a relationship between inactivating mutations in NCC and oestrogen level disturbances, making it unlikely that oestrogen affects DCT-mediated Mg\(^{2+}\) reabsorption in patients with Na\(^{+}\) wasting disorders.

### 2.3 Could a depolarised membrane potential difference reduce Mg\(^{2+}\) reabsorption?

In the DCT, there is no chemical gradient for Mg\(^{2+}\) reabsorption since the extracellular and intracellular Mg\(^{2+}\) concentration are within the same range. TRPM6-mediated Mg\(^{2+}\) influx in the DCT, therefore, depends solely on the electrical gradient.\(^{51}\) Consequently, maintaining the apical membrane potential difference is essential for Mg\(^{2+}\) reabsorption in this segment. Since Na\(^{+}\) and Cl\(^{-}\) co-transport is electroneutral, and is not dependent on the apical membrane potential difference, it is unlikely that NCC directly affects TRPM6-mediated Mg\(^{2+}\) transport. Studies in immortalized mouse DCT cells demonstrated that a reduced apical membrane potential significantly decreased Mg\(^{2+}\) uptake.\(^{139}\) It has been postulated that the apical K\(^{+}\) channel Kv1.1 contributes to the apical membrane potential difference, which would facilitate Mg\(^{2+}\) influx.\(^{50,51,140}\) Although direct membrane potential measurements in the DCT are technically challenging and therefore not available, a depolarised state of the apical membrane will inevitably result in a reduced driving force for apical Mg\(^{2+}\) transport via TRPM6.

The Na\(^{+}\)-K\(^{+}\)-ATPase plays a central role in DCT physiology, specifically in electrogenic ion transport (Figure 1). The DCT has the highest activity of this heterodimer within the kidney, which is accompanied with the highest density of mitochondria as generator of ATP.\(^{141}\) The Na\(^{+}\)-K\(^{+}\)-ATPase provides the driving force that is required for NCC activity, and sets the basolateral membrane potential difference at ±70 mV. Mutations in ATP1A1 and FXYD2, encoding the alpha and gamma subunits, respectively, of the Na\(^{+}\)-K\(^{+}\)-ATPase have been associated with hypomagnesaemia and renal Mg\(^{2+}\) wasting.\(^{142-144}\) Moreover, prolonged treatment with Na\(^{+}\)-K\(^{+}\)-ATPase inhibitors increased the incidence of hypomagnesaemia.\(^{145,146}\) These findings highlight the importance of the Na\(^{+}\)-K\(^{+}\)-ATPase for renal Mg\(^{2+}\) reabsorption (Figure 5).

Salt-wasting disorders of the DCT indirectly cause decreased Na\(^{+}\)-K\(^{+}\)-ATPase activity. As Kir4.1 is essential for basolateral K\(^{+}\) recycling at the basolateral membrane, Kir4.1 mutations that cause EAST/SeSAME syndrome, impair Na\(^{+}\)-K\(^{+}\)-ATPase activity.\(^{16,69,147}\) By uncoupling the “pump-leak mechanism” at the basolateral membrane, the plasma membrane will be depolarised via reduced Kir4.1 K\(^{+}\) extrusion. This would limit the Cl\(^{-}\) extrusion via CIC-Kb, lead to an increased intracellular Cl\(^{-}\) concentration, the inhibition of WNK kinases, and ultimately inhibited NCC-mediated Na\(^{+}\) reabsorption. Indirectly, changes in the basolateral membrane potential could thereby regulate NCC function. On the other hand, interestingly, although Na\(^{+}\)-K\(^{+}\)-ATPase activity has never been directly assessed in Gitelman syndrome, data from thiazide-treated
rats demonstrate reduced Na\(^+\)-K\(^+\)-ATPase activity in the DCT.\(^{148}\) Upon thiazide treatment, the reduced NCC activity may decrease the intracellular Na\(^+\) in the DCT, reducing the Na\(^+\) supply to the Na\(^+\)-K\(^+\)-ATPase. Indeed, Na\(^+\)-K\(^+\)-ATPase activity in the proximal tubule and loop of Henle was not altered by thiazide treatment.\(^{148}\)
Given that the Na\(^+\)-K\(^+\)-ATPase is crucial for the K\(^+\) recycling and thereby contributes to K\(^+\) permeability, its reduced activity in EAST/SeSAME and Gitelman syndrome will result in a depolarised basolateral membrane. Basolateral Mg\(^{2+}\) extrusion is generally considered to be Na\(^+\) dependent. A wide range of experiments in different cell types have demonstrated the presence of a Na\(^+\)-Mg\(^{2+}\) exchange mechanism.\(^{149}\) Reduced Na\(^+\)-K\(^+\)-ATPase in salt-wasting syndrome of the DCT may, therefore, directly reduce the Na\(^+\) gradient that is required for Mg\(^{2+}\) extrusion. Although the exact molecular identity of the Mg\(^{2+}\) extrusion mechanism is under debate, Kolisek and colleagues have advocated that SLC41A1 functions as Na\(^+\)-Mg\(^{2+}\) exchanger in a 2:1 stoichiometry.\(^{150,151}\) However, the Na\(^+\) dependence of Mg\(^{2+}\) efflux via SLC41A1 is under debate.\(^{150}\) Arjona et al recently showed that SLC41A1 facilitates Na\(^+\) and Cl\(^-\) independent Mg\(^{2+}\) efflux in overexpression models.\(^{152}\) Further studies in native DCT cells are required to further elucidate this mechanism. The nature of the Mg\(^{2+}\) extrusion mechanism is important to understand the effects of Gitelman and EAST/SeSAME syndrome on Mg\(^{2+}\) reabsorption.

## Conclusion and perspectives

Na\(^+\) and Mg\(^{2+}\) reabsorption in the DCT are closely coupled. Atrophy of the DCT caused by loss of NCC activity is the most supported hypothesis to explain hypomagnesaemia in Na\(^+\) wasting disorders. Although these data are mainly obtained in animal models and biopsies of Gitelman patients are rarely executed, recent data suggest that progressive regression of the DCT explains the late clinical onset of the syndrome.\(^{93}\) However, hormonal pathways that co-regulate NCC and TRPM6 and the effects of changed basolateral Na\(^+\) and K\(^+\) transport cannot be excluded and may also contribute to hypomagnesaemia.

In conclusion, further studies should provide final answers on the coupling of Na\(^+\) and Mg\(^{2+}\) reabsorption of the DCT. Our comprehensive analysis shows that this process is not dependent on a single factor, emphasizing the complexity of experimental design mimicking physiologically representative conditions. Recent advances in kidney organoid cultures may provide an advanced tool to dissect how Mg\(^{2+}\) transport is dependent on NaCl reabsorption, as they provided insights in other congenital disorders.\(^{153-155}\) Dissecting the underlying molecular mechanisms would not only add to the fundamental knowledge of ion transport in the kidney but it would also be an invaluable addition towards understanding the development of hypomagnesaemia in inherited Na\(^+\) wasting disorders.

## Acknowledgements

We thank Wouter van Megen for proof-reading the manuscript and providing feedback. This work was financially supported by grants from the Netherlands Organization for Scientific Research (NWO Veni 016.186.012).

## Conflicts of interest

None.

## ORCID

Gijs A. C. Franken \(\text{https://orcid.org/0000-0001-6521-1026}\)

Anastasia Adella \(\text{https://orcid.org/0000-0001-5712-6112}\)

René J. M. Bindels \(\text{https://orcid.org/0000-0003-1167-1339}\)

Jeroen H. F. de Baaij \(\text{https://orcid.org/0000-0003-2372-8486}\)

## References

1. Hierholzer K, Wiederholt M. Some aspects of distal tubular solute and water transport. *Kidney Int*. 1976;9(2):198-213.

2. van der Lubbe N, Lim CH, Meima ME, et al. Aldosterone does not require angiotensin II to activate NCC through a WNK4-SPAK-dependent pathway. *Pflugers Arch*. 2012;463(6):853-863.

3. Chiga M, Rai T, Yang SS, et al. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. *Kidney Int*. 2008;74(11):1403-1409.

4. Ko B, Mistry AC, Hanson L, et al. Aldosterone acutely stimulates NCC activity via a SPAK-mediated pathway. *Am J Physiol Renal Physiol*. 2013;305(5):F645-F652.

5. Chavez-Canales M, Arroyo JP, Ko B, et al. Insulin increases the functional activity of the renal NaCl cotransporter. *J Hypertens*. 2013;31(2):303-311.

6. Sohara E, Rai T, Yang SS, et al. Acute insulin stimulation induces phosphorylation of the Na-CI cotransporter in cultured distal mpkDCT cells and mouse kidney. *PLoS One*. 2011;6(8):e24277.

7. Lee CT, Lien YH, Lai LW, Chen JB, Lin CR, Chen HC. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. *Kidney Int*. 2006;69(10):1786-1791.

8. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. *J Clin Invest*. 2007;117(8):2260-2267.

9. Thebault S, Alexander RT, Tiel Groenestege WM, Hoenderop JG, Bindels RJ. EGF increases TRPM6 activity and surface expression. *J Am Soc Nephrol*. 2009;20(1):78-85.

10. Nair AV, Hocher B, Verkaart S, et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. *Proc Natl Acad Sci USA*. 2012;109(28):11324-11329.

11. Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. *J Clin Invest*. 1989;83(1):113-126.

12. Loffing J, Vallon V, Loffing-Cueni D, et al. Altered renal distal tubule structure and renal Na(+)+ and Ca(2+) handling in a mouse model for Gitelman’s syndrome. *J Am Soc Nephrol*. 2004;15(9):2276-2288.

13. Schultheis PJ, Lorenz JN, Meneton P, et al. Phenotype resembling Gitelman’s syndrome in mice lacking the apical
Na\textsuperscript{+}-Cl\textsuperscript{−} cotransporter of the distal convoluted tubule. *J Biol Chem.* 1998;273(44):29150-29155.

14. Accogli A, Scala M, Calcagno A, et al. CNNM2 homozygous mutations cause severe refractory hypomagnesemia, epileptic encephalopathy and brain malformations. *Eur J Med Genet.* 2019;62(3):198-203.

15. Zhang C, Wang L, Zhang J, et al. KCNJ10 determines the expression of the apical NaCl cotransporter (NCC) in the early distal convoluted tubule (DCT1). *Proc Natl Acad Sci USA.* 2014;111(32):11864-11869.

16. Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensory neurone deafness, tubulopathy, and KCNJ10 mutations. *N Engl J Med.* 2009;360(19):1960-1970.

17. Kompatscher A, de Baaij JHF, Aboudehen K, et al. Loss of ATP and magnesium drive conformational changes of the Na\textsuperscript{+}/K\textsuperscript{+}-ATPase cytoplasmic headpiece. *J Biol Chem.* 2017;92(5):1145-1156.

18. Palygin O, Pochynyuk O, Staruschenko A. Distal tubule basolateral potassium channels: cellular and molecular mechanisms of regulation. *Curr Opin Nephrol Hypertens.* 2018;27(5):373-378.

19. Sachs JR. Interaction of magnesium with the sodium pump of the human red cell. *J Physiol.* 1988;400:575-591.

20. Apell HJ, Hitzler T, Schreiber G. Modulation of the Na, K-ATPase by magnesium ions. *Biochemistry.* 2017;56(7):1005-1016.

21. Grycova L, Sklenovsky P, Landsky Z, et al. ATP and magnesium phosphorylation of the Na\textsuperscript{+}/K\textsuperscript{+}-ATPase cytoplasmic headpiece. *Biochimica et Biophysica Acta (BBA) - Biomembranes.* 2009;1788(5):1081-1091.

22. Schultz SG. Pump-leak parallelism in sodium-absorbing epithelia: the role of ATP-regulated potassium channels. *J Exp Zool.* 1997;279(5):476-483.

23. Gamba G. Regulation of the renal Na\textsuperscript{+}-Cl\textsuperscript{−} cotransporter by phosphorylation and ubiquitylation. *Am J Physiol Renal Physiol.* 2012;303(12):F1573-1583.

24. Pacheco-Alvarez D, Cristobal PS, Meade P, et al. The Na\textsuperscript{+}-Cl\textsuperscript{−} cotransporter is activated and phosphorylated at the amino-terminal domain upon intracellular chloride depletion. *J Biol Chem.* 2006;281(39):28755-28763.

25. Richardson C, Rafaqi FH, Karlsson HK, et al. Activation of the thiazide-sensitive Na\textsuperscript{+}-Cl\textsuperscript{−} cotransporter by the WNK-regulated kinases SPAK and OSR1. *J Cell Sci.* 2008;121(Pt 5):675-684.

26. Gordon RD. The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon’s syndrome. *Aust NZ J Med.* 1986;16(2):183-184.

27. Vitari AC, Deak M, Morrice NA, Alessi DR. The WNK1 and WNK4 protein kinases that are mutated in Gordon’s hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. *Biochem J.* 2005;391(Pt 1):17-24.

28. Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertonph caused by mutations in WNK kinases. *Science.* 2001;293(5532):1107-1112.

29. Boyden LM, Choi M, Choate KA, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature.* 2012;482(7383):98-102.

30. McCormick JA, Yang CL, Zhang C, et al. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3. *J Clin Invest.* 2014;124(11):4723-4736.

31. Ohta A, Schumacher FR, Mebellou Y, et al. The CUL3-KLHL3 E3 ligase complex mutated in Gordon’s hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. *Biochem J.* 2013;451(1):111-122.

32. Terker AS, Zhang C, McCormick JA, et al. Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. *Cell Metab.* 2015;21(1):39-50.

33. Vallon V, Schroth J, Lang F, Kuhl D, Uchida S. Expression and phosphorylation of the Na\textsuperscript{+}-Cl\textsuperscript{−} cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. *Am J Physiol Renal Physiol.* 2009;297(3):F704-F712.

34. van der Lubbe N, Moeis AD, Rosenbaek LL, et al. K\textsuperscript{+}-induced natriuresis is preserved during Na\textsuperscript{+} depletion and accompanied by inhibition of the Na\textsuperscript{+}-Cl\textsuperscript{−}-cotransporter. *Am J Physiol-Renal Physiol.* 2013;305(8):F1177-F1188.

35. Vitzthum H, Seniuk A, Schulte LH, Muller ML, Hetz H, Ehmk H. Functional coupling of renal K\textsuperscript{+} and Na\textsuperscript{+} handling causes high blood pressure in Na\textsuperscript{+} replete mice. *J Physiol.* 2014;592(5):1139-1157.

36. vanderWijst J, TutakheOAZ, Bos C, et al. Effects of a high-sodium/low-potassium diet on renal calcium, magnesium, and phosphate handling. *Am J Physiol Renal Physiol.* 2018;315(1):F110-F122.

37. Cuevas CA, Su XT, Wang MX, et al. Potassium sensing by renal distal tubules requires Kir4.1. *J Am Soc Nephrol.* 2017;28(6):1814-1825.

38. Min X, Lee BH, Cobb MH, Goldsmith EJ. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. *Structure.* 2004;12(7):1303-1311.

39. Piala AT, Moon TM, Akella R, He H, Cobb MH, Goldsmith EJ. Chloride sensing by WNK1 involves inhibition of autophosphorylation. *Sci Signal.* 2014;7(324):ra41.

40. Wei Y, Zavilowitz B, Satlin LM, Wang W-H. Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. *J Biol Chem.* 2007;282(9):6455-6462.

41. Yue P, Sun P, Lin DH, Pan C, Xing W, Wang W. Angiotensin II diminishes the effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. *Kidney Int.* 2011;79(4):423-431.

42. Kahle KT, Wilson FH, Leng Q, et al. WNK4 regulates the balance between renal NaCl reabsorption and K\textsuperscript{+} secretion. *Nat Genet.* 2003;35(4):372-376.

43. Ring AM, Cheng SX, Leng Q, et al. WNK4 regulates activity of the epithelial Na\textsuperscript{+} channel in vitro and in vivo. *Proc Natl Acad Sci USA.* 2007;104(10):4020-4024.

44. Yu L, Cai H, Yue Q, et al. TRPM6 kinase activity regulates TRPM7 trafficking and inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. *J Biol Chem.* 2009;284(8):5685-5692.
49. Luongo F, Pietropaolo G, Gautier M, et al. TRPM6 is essential for magnesium uptake and epithelial cell function in the colon. *Nutrients*. 2018;10(6):784

50. van der Wijst J, Glaudemans B, Venselaar H, et al. Functional analysis of the Kv1.1 N255D mutation associated with autosomal dominant hypomagnesemia. *J Biol Chem*. 2010;285(1):171-178.

51. Glaudemans B, van der Wijst J, Scola RH, et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNMA1 is linked to human autosomal dominant hypomagnesemia. *J Clin Invest*. 2009;119(4):936-942.

52. Dimke H, van der Wijst J, Alexander TR, et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. *J Am Soc Nephrol*. 2010;21(8):1309-1316.

53. Groeneveste WM, Hoenderop JG, van den Heuvel L, Knoers NV, Bindels RJ. The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ content and estrogen. *J Am Soc Nephrol*. 2006;17(4):1035-1043.

54. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat Genet*. 2002;31(2):166-170.

55. Schlingmann KP, Sassen MC, Weber S, et al. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. *J Am Soc Nephrol*. 2005;16(10):3061-3069.

56. Guther T, Vormann J, Forster R. Regulation of intracellular Mg2+ in primary hyperkalaemic periodic paralysis. *Biochem Biophys Res Commun*. 1984;119(1):124-131.

57. Romani AM. Cellular magnesium homeostasis. *Arch Biochem Biophys*. 2011;512(1):1-23.

58. Kolisek M, Launay P, Beck A, et al. SLC41A1 is a novel mammalian Mg2+ carrier. *J Biol Chem*. 2008;283(23):16235-16247.

59. Hurd TW, Otto EA, Mishima E, et al. Mutation of the Mg2+ transporter SLC41A1 results in a nephronophthisis-like phenotype. *Nat Genet*. 2011;88(3):333-343.

60. Stuiver M, Lainez S, Will C, et al. CNNM2, encoding a basolateral Mg2+ transporter SLC41A1, is mutated in a nephronophthisis patient. *Hum Genet*. 2011;129(5):511-516.

61. de Baaij JH, Stuiver M, Meij IC, et al. Membrane topology and intracellular processing of cyclin M2 (CNNM2). *J Biol Chem*. 2012;287(17):13644-13655.

62. Arjona FJ, de Baaij JH, Schlingmann KP, et al. CNNM2 mutations cause impaired brain development and seizures in patients with hypomagnesemia. *PLoS Genet*. 2014;10(4):e1004267.

63. Arjona FJ, de Baaij JH. CrossTalk opposing view: CNNM2 proteins are not Na+/Mg2+ exchangers but Mg2+ transport regulators playing a central role in transepithelial Mg2+ (re)absorption. *J Physiol*. 2018;596(5):747-750.

64. Funato Y, Furutani K, Kuriyama M, Hakamata H, Beutella from Yosuke Funato, Kazuharu Furutani, Yoshikusa Kuriyama and Hiroaki Miki. *J Physiol*. 2018;596(5):751.

65. Arjona FJ, de Baaij JH. Factor-targeting antibody against STIM1 and PAR3 regulates epithelial Mg2+ transport. *J Physiol*. 2018;596(5):753-754.

66. Goudevenos J, Elisaf MS. Recent advances in magnesium metabolism and its role in congestive heart failure. *Nat Rev Cardiol*. 2018;15(11):651-666.

67. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat Genet*. 1996;12(1):24-30.

68. Bartter FC, Pronove P, Gill JR Jr, Maccardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. *Am J Med*. 1962;33:811-828.

69. Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. *Proc Natl Acad Sci USA*. 2009;106(14):5842-5847.

70. Birkenhager R, Otto E, Schurmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. *Nat Genet*. 2001;29(3):310-314.

71. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet*. 1996;13(2):183-188.

72. Simon DB, Karet FE, Rodriguez-Soriano J, et al. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the Kv1.1 channel. *Nat Genet*. 1996;14(2):152-156.

73. Matsunoshita N, Nozu K, Shono A, et al. Differential diagnosis of Bartter syndrome, Gitelman syndrome, and pseudo-Bartter/Gitelman syndrome based on clinical characteristics. *Genet Med*. 2016;18(2):180-188.

74. Walsh PR, Tse Y, Ashton E, et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. *Clin Kidney J*. 2018;11(3):302-309.

75. Al Shibli A, Narchi H, Bartter and Gitelman syndromes: spectrum of clinical manifestations caused by different mutations. *World J Methodol*. 2015;5(2):55-61.

76. Jeck N, Schlingmann KP, Reinalter SC, et al. Salt handling in the distal nephron: lessons learned from inherited human disorders. *Am J Physiol-Regul Integr Comp Physiol*. 2005;288(4):R782-R795.

77. Kierboom BCT, Zietse R, Ikram MA, Hoorn EJ, Stricker BH. Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population. *Pharmacoepidemiol Drug Saf*. 2018;27(11):1166-1173.

78. Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesaemia and concurrent acid–base and electrolyte abnormalities in patients with congestive heart failure. *Eur J Heart Fail*. 2002;4(2):167-173.

79. Cohen N, Almoznino-Sarafian D, Zaidenstein R, et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. *Heart*. 2003;89(4):411-416.

80. van Angelen AA, van der Kemp AW, Hoenderop JG, Bindels RJ. Increased expression of renal TRPM6 compensates for Mg2+ wasting during furosemide treatment. *Clin Kidney J*. 2012;5(6):535-544.

81. Tejpar S, Pissessian H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. *Lancet Oncol*. 2007;8(5):387-394.

82. Melchior B, Kralickova P, Hyspler R, et al. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab. *Hepatogastroenterology*. 2012;59(14):366-371.

83. Price T, Kim TW, Li J, et al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia. *BMC Cancer*. 2012;12:458.

84. Bartter FC, Pronove P, Gill JR Jr, Maccardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. *Am J Med*. 1962;33:811-828.
84. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. *JNCI*. 2005;97(16):1221-1224.

85. Grateak BD, Swanson EA, Lazelle RA, et al. Tacrolimus-induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin. *Physiol Rep*. 2020;8(1):e14316.

86. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholnder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. *Am J Transplant*. 2009;9(9):2140-2149.

87. Alexandre CDS, de Bragança AC, Shimizu MHM, et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. *Am J Physiol-Renal Physiol*. 2009;297(4):F916-F922.

88. Yang SS, Lo YF, Wu CC, et al. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. *J Am Soc Nephrol*. 2010;21(11):1868-1877.

89. McCormick JA, Mutig K, Nelson JH, et al. A SPAK isoform switch modulates renal salt transport and blood pressure. *Cell Metab*. 2011;14(3):352-364.

90. Grimm PR, Lazo-Fernandez Y, Delpere E, et al. Integrated compensatory network is activated in the absence of NCC phosphorylation. *J Clin Invest*. 2015;125(5):2136-2150.

91. Verouti SN, Boscardin E, Hummeler E, Frateschi S. Regulation of blood pressure and renal function by NCC and ENaC: lessons from genetically engineered mice. *Curr Opin Pharmacol*. 2015;21:60-72.

92. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. *J Clin Invest*. 2005;115(6):1651-1658.

93. Schnoz C, Carrel M, Loffing J. Loss of sodium chloride co-transporter impairs the outgrowth of the renal distal convoluted tubule during renal development. *Nephrol Dial Transplant*. 2019;35(3):411–432.

94. Yang SS, Lo YF, Yu IS, et al. Generation and analysis of the thiazide-sensitive Na+-Cl− cotransporter (Ncc/Slc12a3) Ser707X knockin mouse as a model of Gitelman syndrome. *Hum Mutat*. 2010;31(12):1304-1315.

95. Lalioti MD, Zhang J, Volkman HM, et al. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. *Nat Genet*. 2006;38(10):1124-1132.

96. Grimm PR, Coleman R, Delpere E, Welling PA. Constitutively active SPAK causes hyperkalemia by activating NCC and Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. *J Am Soc Nephrol*. 2001;12(7):1335-1341.

97. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. *J Am Soc Nephrol*. 2006;290(1):H2552-H2557.

98. Arroyo JP, Lagnaz D, Ronzaud C, et al. Nedd4-2 modulates renal Na+−Cl− cotransporter via the aldosterone-SGK1-Nedd4-2 pathway. *J Am Soc Nephrol*. 2011;22(9):1707-1719.

99. Terker AS, Yarbrough B, Ferdaus MZ, et al. Direct and indirect mineralocorticoid effects determine distal salt transport. *J Am Soc Nephrol*. 2016;27(8):2436-2445.

100. van Megen WH, Grimm PR, Welling PA, van der Wijst J. Renal sodium and magnesium reabsorption are not coupled in a mouse model of Gordon syndrome. *Physiol Rep*. 2018;6(14):e13728.

101. Toh TH, Tong CV, Chong HC. Primary aldosteronism—not just about potassium and blood pressure. *QJM Int J Med*. 2011;110(3):175-177.

102. Chhokar Vikram S, Sun Y, Bhattacharyya Syamal K, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. *Circulation*. 2005;111(7):871-878.

103. Vidal A, Sun Y, Bhattacharyya SK, Ahocas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. *Am J Physiol-Heart Circ Physiol*. 2006;290(3):H86-H294.

104. Sontia B, Montezano AC, Paravincini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. *Hypertension*. 2008;51(4):915-921.

105. Yogi A, Callera GE, O’Connor SE, et al. Dysregulation of renal transient receptor potential melastatin 7 and not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. *J Hypertens*. 2011;29(7):1400-1410.

106. Yogi A, Callera GE, O’Connor S, et al. Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its alpha-kinase domain. *Cell Signal*. 2013;25(11):2163-2175.

107. Valinsky WC, Jolly A, Miquel P, Touyz RM, Shrier A. Aldosterone upregulates transient receptor potential melastatin 7 (TRPM7). *J Biol Chem*. 2016;291(38):20163-20172.
138. Cao G, van der Wijst J, van der Kemp A, van Zeeland F, Bindels RJ, Hoenderop JG. Regulation of the epithelial Mg\(^{2+}\) channel TRPM6 by estrogen and the associated repressor protein of estrogen receptor activity (REA). *J Biol Chem*. 2009;284(24):14788-14795.

139. Dai LJ, Raymond L, Friedman PA, Quamme GA. Mechanisms of amiloride stimulation of Mg\(^{2+}\) uptake in immortalized mouse distal convoluted tubule cells. *Am J Physiol*. 1997;272(2 Pt 2):F249-F256.

140. Carrizoza-Gaytan R, Salvador C, Diaz-Bello B, Escobar LI. Differential expression of the Kv1 voltage-gated potassium channel family in the rat nephron. *J Mol Histol*. 2014;45(5):583-597.

141. Schlingmann KP, Bandulik S, Mammen C, et al. Germline de novo mutations in ATP1A1 cause renal hypomagnesemia, refractory seizures, and intellectual disability. *Am J Hum Genet*. 2018;103(5):808-816.

142. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. *Arch Intern Med*. 1985;145(4):655-656.

143. Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. *Br J Clin Pharmacol*. 1991;32(6):717-721.

144. Williams DM, Lopes CM, Rosenhouse-Dantsker A, et al. Recurrent FXYD2 p.Gly41Arg mutation in patients with isolated dominant hypomagnesemia. *Nephrol Dial Transplant*. 2015;30(6):952-957.

145. Christy NP, Shaver JC. Estrogens and the kidney. *Kidney Int*. 1974;37(2):152-157.

146. Yuan T, Jiang L, Chen C, et al. Glucose tolerance and insulin resistance in Gitelman syndrome patients. *Endocr Connect*. 2017;6(4):243-252.

147. Blanchard A, Vallet M, Dubourg L, et al. Resistance to insulin in Chinese patients with Gitelman syndrome. *Am J Nephrol*. 2013;37(2):152-157.

148. Meij IC, Koenderink JB, van Bokhoven H, et al. Dominant isolated renal magnesium loss is caused by misrouting of the Na(+), K(+)-ATPase gamma-subunit. *Nat Genet*. 2000;26(3):265-266.

149. Chung CH, Leggett ML, Oslin DW, et al. Role of estrogen substitutional therapy on magnesium metabolism. *Miner Electrolyte Metab*. 1991;16(2):434-444.

150. McNair P, Christiansen C, Transbol I. Effect of hormone therapy on calcium. *Magnes Trace Elem*. 1999;16(4):442-458.
154. Forbes TA, Howden SE, Lawlor K, et al. Patient-iPSC-derived kidney organoids show functional validation of a ciliopathic renal phenotype and reveal underlying pathogenetic mechanisms. *Am J Hum Genet*. 2018;102(5):816-831.

155. Przepiorski A, Sander V, Tran T, et al. A simple bioreactor-based method to generate kidney organoids from pluripotent stem cells. *Stem Cell Reports*. 2018;11(2):470-484.

156. Viering D, de Baaij JHF, Walsh SB, Kleta R, Bockenhauer D. Genetic causes of hypomagnesemia, a clinical overview. *Pediatr Nephrol*. 2017;32(7):1123-1135.

157. Simon DB, Bindra RS, Mansfield TA, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. *Pediatr Nephrol*. 1997;17(2):171-178.

158. Bettinelli A, Rusconi R, Ciarmatori S, et al. Gitelman disease associated with growth hormone deficiency, disturbances in vasopressin secretion and empty sella: a new hereditary renal tubular-pituitary syndrome? *Pediatr Res*. 1999;46(2):232-238.

159. Knoers NV, Levchenko EN. Gitelman syndrome. *Orphanet J Rare Dis*. 2008;3:22.

160. Picard HLD, Thurairajasingam N, Decramer S, et al. 1A.01: mutations affecting the conserved acidic motif of Wnk1 cause inherited normotensive hyperkalemic acidosis. *J Hypertens*. 2015;33:e1.

161. Schambelan M, Sebastian A, Rector FC. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. *Kidney Int*. 1981;19(5):716-727.

162. Furgeson SB, Linas S. Mechanisms of type I and type II pseudohypoaldosteronism. *J Am Soc Nephrol*. 2010;21(11):1842-1845.

163. Louis-Dit-Picard H, Barc J, Trujillano D, et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. *Nat Genet*. 2012;44(4):456-460.

164. van der Wijst J, Konrad M, Verkaart SAJ, et al. A de novo KCNA1 mutation in a patient with tetany and hypomagnesemia. *Nephron*. 2018;139(4):359-366.

165. Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat Genet*. 2002;31(2):171-174.

How to cite this article: Franken GAC, Adella A, Bindels RJM, de Baaij JHF. Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney. *Acta Physiol*. 2021;231:e13528. [https://doi.org/10.1111/apha.13528](https://doi.org/10.1111/apha.13528)